<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This paper describes the case of a male child with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> who developed cerebral sinovenous <z:mp ids='MP_0005048'>thrombosis</z:mp> on day 6 of induction therapy with intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>A central venous catheter had been implanted the day before </plain></SENT>
<SENT sid="2" pm="."><plain>The heterozygous prothrombin G20210A variant was found together with acquired activated protein C resistance and a reduced activated partial thromboplastin time </plain></SENT>
<SENT sid="3" pm="."><plain>Clinical course and magnetic resonance imaging with magnetic resonance venography gradually improved over the following days after starting <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy (<z:chebi fb="5" ids="28304">heparin</z:chebi> and nadroparin) </plain></SENT>
<SENT sid="4" pm="."><plain>Cerebral sinovenous <z:mp ids='MP_0005048'>thrombosis</z:mp> is a serious disease in leukemic children, occurring in up to 6% of these patients </plain></SENT>
<SENT sid="5" pm="."><plain>Data from the literature are in favor of anti-coagulant treatment, even though the efficacy and safety of thromboprophylaxis during chemotherapy in leukemic children with inherited thrombophilic conditions remain to be demonstrated </plain></SENT>
</text></document>